CBER Director Zoon Leaving FDA, Will Assume Position At NCI In January
This article was originally published in The Gray Sheet
Executive Summary
Center for Biologics Evaluation & Research Director Kathryn Zoon's January departure coincides with the establishment of the FDA office of combination products under MDUFMA
You may also be interested in...
Biotech Ethics Council Urged By Former FDAer/AdvaMed VP Benson
An advisory panel should be created to consider moral and ethical biotechnology issues faced by FDA and other health agencies, according to former FDA Acting Commissioner James Benson
Biotech Ethics Council Urged By Former FDAer/AdvaMed VP Benson
An advisory panel should be created to consider moral and ethical biotechnology issues faced by FDA and other health agencies, according to former FDA Acting Commissioner James Benson
CBER Deputy Director Goodman To Assume Biologics Directorship In January
Incoming Center for Biologics Evaluation & Research Director Jesse Goodman, MD, brings a working relationship with blood test manufacturers from his experience as CBER deputy director